Abbott Healthcare, GlaxoSmithKline hit most by fresh control on drug prices – dnaindia.com
0
The move by National Pharmaceutical Pricing Authority (NPPA) to cap prices of 52 formulations may not hit drug makers much as the total market size of these drugs is Rs 123 crore.
Of this the value loss due to lowering MRP to ceiling prices set by the regulator would be 14% of the total Rs 123 crore.
Read more – dnaindia.com